Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
暂无分享,去创建一个
Sydney M. Shaffer | A. Raj | M. Herlyn | Abhyudai Singh | K. Nathanson | S. Shaffer | E. Torre | M. Xiao | Benjamin L. Emert | C. A. Vargas-Garcia | Margaret C. Dunagin | P. Brafford | Ioannis N. Anastopoulos | Stefan R. Torborg | C. Krepler | M. Beqiri | Katrin Sproesser | Elliott R Eggan | M. Xiao | Ioannis Anastopoulos | Patricia Brafford
[1] Guocheng Yuan,et al. GiniClust: detecting rare cell types from single-cell gene expression data with Gini index , 2016, Genome Biology.
[2] Arjun Raj,et al. What's Luck Got to Do with It: Single Cells, Multiple Fates, and Biological Nondeterminism. , 2016, Molecular cell.
[3] S. Tavazoie,et al. Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness , 2016, Nature Communications.
[4] Charles H. Yoon,et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.
[5] Bruce A. Posner,et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.
[6] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[7] L. Pelkmans,et al. Control of Transcript Variability in Single Mammalian Cells , 2015, Cell.
[8] G. Mills,et al. Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies , 2015, Clinical Cancer Research.
[9] Samantha E. Boyle,et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma , 2015, Science Signaling.
[10] A. Pisco,et al. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.
[11] A. Raj,et al. Single mammalian cells compensate for differences in cellular volume and DNA copy number through independent global transcriptional mechanisms. , 2015, Molecular cell.
[12] S. Aerts,et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.
[13] T. Graeber,et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.
[14] Timur Zhiyentayev,et al. Single-cell in situ RNA profiling by sequential hybridization , 2014, Nature Methods.
[15] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[16] A. Weeraratna,et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.
[17] Howard Y. Chang,et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.
[18] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.
[19] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Weeraratna,et al. A Wnt-er Migration: The Confusing Role of β-Catenin in Melanoma Metastasis , 2013, Science Signaling.
[21] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[22] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[23] B. Neyns,et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.
[24] David Liao,et al. Conceptualizing a tool to optimize therapy based on dynamic heterogeneity , 2012, Physical biology.
[25] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[26] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.
[27] Guy S. Salvesen,et al. SnapShot: Caspases , 2011, Cell.
[28] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[29] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[30] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[31] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[32] M. Delbrück,et al. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.